A Game-Changer for Gilead Sciences?

Recent fourth quarter results from Gilead Sciences, Inc. (NASDAQ: GILD) were upbeat, but are they a game-changer?

Feb 10, 2014 at 9:58PM

Investors in Gilead Sciences (NASDAQ:GILD) had something to shout about last week as the company beat Wall Street estimates when it reported its fourth-quarter results.

While the results showed that earnings per share were the same as in the fourth quarter of 2012 at $0.47, they beat Wall Street estimates. Furthermore, revenue also beat Wall Street estimates of $2.85 billion, rising by 20% to hit $3.12 billion.

The EPS figure is slightly misleading, as quarterly profit increased by 4% to $791 million but, on a per-share basis, it stayed the same simply because of an increase in the number of shares in issue. So both the top line and bottom line grew when compared with the fourth quarter of 2012, giving investors something to cheer about.

A key reason behind the growth in sales and profits for Gilead was sales of its hepatitis C drug, Sovaldi, which amounted to $140 million following approval of the drug in December. This is highly encouraging news for investors in Gilead, and with the drug's having been approved in Canada (also in December) as well as the European Union (in January), Sovaldi could prove to be a blockbuster drug for Gilead in 2014.

Sovaldi appears to be an improvement on current treatments for hepatitis C, with incumbent Incivek (sold by Johnson & Johnson (NYSE:JNJ) and Vertex Pharmaceuticals (NASDAQ:VRTX)) taking longer to treat the illness and having a lower success rate. Interestingly, Vertex recently sold the overseas rights of Incivek to Johnson & Johnson for $152 million as domestic sales of the drug fell by 91% in the fourth quarter of 2013 -- highlighting the strength of Sovaldi sales in December.

While Sovaldi cured around 90% of patients with hepatitis C after 12 weeks of treatment in clinical trials, Incivek cures around 75% of patients over the course of a year. Furthermore, patients treated with Sovaldi don't need to take interferon, an injectable drug that can cause diarrhea, so long as Sovaldi is taken alongside ribavirin. This, coupled with the relatively high success rate of the drug and its relatively short treatment time, means that it could become a blockbuster for Gilead in 2014.

Of course, Johnson & Johnson had a new drug for the treatment of hepatitis C approved in late 2013, too. However, it seems as though Sovaldi could win the race, as Gilead seeks out additional combination drugs to be used alongside Sovaldi.

Meanwhile, Gilead also saw strength in sales of its antiviral and cardiovascular products, with the former increasing sales by 22% and the latter by 25% when compared with the fourth quarter of 2013. Of particular note were Complera and Eviplera, where sales more than doubled to $260 million, while Stribild saw sales increase from $40 million to more than $200 million.

Guidance for 2014 seems encouraging, although Gilead has excluded sales of Sovaldi from its forecasts. However, with an impressive level of uptake since approval on Dec. 6 and the anticipation that it could be a blockbuster drug, Sovaldi could be a game-changer for Gilead in 2014.

2 game-changing biotechs
The best way to play the biotech space is to find companies that shun the status quo and instead discover revolutionary, groundbreaking technologies. In The Motley Fool's brand-new free report "2 Game-Changing Biotechs Revolutionizing the Way We Treat Cancer," find out about a new technology that Big Pharma is endorsing through partnerships, and the two companies that are set to profit from this emerging drug class. Click here to get your copy today.

Peter Stephens has no position in any stocks mentioned. The Motley Fool recommends Gilead Sciences, Johnson & Johnson, and Vertex Pharmaceuticals and owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools dpn't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Money to your ears - A great FREE investing resource for you

The best way to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as “binge-worthy finance.”

Feb 1, 2016 at 5:03PM

Whether we're in the midst of earnings season or riding out the market's lulls, you want to know the best strategies for your money.

And you'll want to go beyond the hype of screaming TV personalities, fear-mongering ads, and "analysis" from people who might have your email address ... but no track record of success.

In short, you want a voice of reason you can count on.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich," rated The Motley Fool as the #1 place online to get smarter about investing.

And one of the easiest, most enjoyable, most valuable ways to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as "binge-worthy finance."

Whether you make it part of your daily commute or you save up and listen to a handful of episodes for your 50-mile bike rides or long soaks in a bubble bath (or both!), the podcasts make sense of your money.

And unlike so many who want to make the subjects of personal finance and investing complicated and scary, our podcasts are clear, insightful, and (yes, it's true) fun.

Our free suite of podcasts

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. The show is also heard weekly on dozens of radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable. Rule Breaker Investing and Answers are timeless, so it's worth going back to and listening from the very start; the other three are focused more on today's events, so listen to the most recent first.

All are available for free at www.fool.com/podcasts.

If you're looking for a friendly voice ... with great advice on how to make the most of your money ... from a business with a lengthy track record of success ... in clear, compelling language ... I encourage you to give a listen to our free podcasts.

Head to www.fool.com/podcasts, give them a spin, and you can subscribe there (at iTunes, Stitcher, or our other partners) if you want to receive them regularly.

It's money to your ears.

 


Compare Brokers